Autolus Limited

Clinical trials sponsored by Autolus Limited, explained in plain language.

Autolus Limited AUTL NASDAQ

Clinical-stage biopharmaceutical company developing CAR-T cell therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Engineered immune cells take on lupus in first human test Results expected Sep 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 4 Not yet finished but already full! 2 Terminated 1

Experimental CAR T-Cell therapy targets tough lymphoma

Disease control Stopped early

This early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The stud…

Phase 1/2 • Sponsor: Autolus Limited • Aim: Disease control

Last updated Jun 27, 2026 11:02 UTC

Autolus Limited

Upcoming readouts

Experimental CAR T-Cell therapy targets tough lymphoma